Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF JUNE 24, 2010 FBO #3134
SPECIAL NOTICE

B -- Tracking Prescribing Patterns and Identifying Strategies to Influence Prescribing Practices

Notice Date
6/22/2010
 
Notice Type
Special Notice
 
NAICS
541690 — Other Scientific and Technical Consulting Services
 
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
 
ZIP Code
20857-0001
 
Solicitation Number
FDA-10-1074431
 
Archive Date
7/13/2010
 
Point of Contact
Tara R. Hobson, Phone: 3018279691, Doreen Williams, Phone: 3018273366
 
E-Mail Address
Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov
(Tara.Hobson@fda.hhs.gov, doreen.williams@fda.hhs.gov)
 
Small Business Set-Aside
N/A
 
Description
Description: Tracking Prescribing Patterns and Identifying Strategies to Influence Prescribing Practices This is an RFI NOTICE to determine the availability and capability of small businesses (i.e. certified 8(a), Small Disadvantaged, and HUBZone firms; veteran and service-disabled veteran-owned small businesses, and woman-owned small businesses) for Tracking Prescribing Patterns and Identifying Strategies to Influence Prescribing Practices. This information is being sought for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the Food and Drug Administration (FDA). No official solicitation exists; therefore, please do not request a copy of a solicitation. If in the future an official solicitation is released, there is no guarantee that sources responding to this will be included on the source list. No telephone inquiries will be accepted. FDA may consider soliciting services for a 2 year contract. Draft Objectives: 1) Assess respective patterns of use of long-acting beta-agonists and long-acting/sustained-release opioid medications to discern suboptimal prescription patterns among users of selected pharmacy benefits providers. 2) Evaluate ability of a prescription- driven feedback program to disseminate FDA safety information. 3) Evaluate the ability of a prescription- driven feedback program to identify and correct potentially suboptimal prescribing practices. Draft Scope of Work: Task 1: Analyze prescribing patterns • A description of the medication use process(es) for the study population that tracks medication flow from prescriber to patient through pharmacy and insurer channels • Quantitative and qualitative information on the population served to include patient demographics, types of providers, insurance carriers, etc. • A data spread sheet depicting baseline and current prescription information for LABAs and LA/SR opioids o The periods for consideration will reflect the nature and timing of the FDA action, amount, and quality of the historical data available to the pharmacy benefits provider. • Types of data to include, if available: o Disease or condition for which the drug is prescribed o For LABAs, whether the prescription is as single agent or in combination with other controller medications o Duration of use o Asthma and opioid-related hospitalizations, emergency department and urgent care visits for patients on these medications Task 2: Evaluate methods within a pharmacy benefit provider to disseminate safety information. • Identify up four FDA initiated communications about the safety of specific drug or drug classes including LABAs, opioids, and possibly 1 or 2 other drug/drug classes if FDA issues a specific safety communication within the first 3 months from start of contract • Develop a protocol consisting of one or more methods to disseminate this information to physicians and other healthcare workers within the pharmacy benefit network. • Evaluate, (e.g., survey data) whether the dissemination plan reached the intended audience and if it altered prescribing practices or let to other changes in behavior Task 3: Evaluate the ability of a prescription- driven feedback program to identify and correct potentially suboptimal LABA and long acting/sustained release opioid prescribing practices Develop a protocol that contains the following elements: • A means to identify potentially suboptimal prescriptions. • A means to identify physicians involved in the potentially suboptimal prescribing • A plan to convey information about optimal prescribing practices; e.g., telephone calls, e - mail communications, facsimile • A method to evaluate outcomes of the different communication strategies We may anticipate a firm fixed price type contract for two years. Viable parties shall provide the following: Part A. Capabilities and Technical Experience - Provide a capability statement describing how your company would provide Tracking Prescribing Patterns and Identifying Strategies to Influence Prescribing Practices as described in the Scope of Work. Part B. Size of Business- Please provide your business size and submit copies of any documentation such as letters or certificates to indicate the firm's status. Part C. Organizational Conflict of Interest (OCI) - If any, provide disclosure of business activities of your company, your affiliates, your team members and affiliates of your team members which create either a conflict of interest or the appearance of a conflict of interest in the Tracking Prescribing Patterns and Identifying Strategies to Influence Prescribing Practices. Part D. Cost Estimate- In accordance with FAR Part 10 Market Research Information; provide a cost estimate for the services (i.e. hourly rates, hours/days) and the number of hours for the Tracking Prescribing Patterns and Identifying Strategies to Influence Prescribing Practices. Part E. Small Business - Describe your ability to meet the requirements in accordance with 52.219.14 - Limitation on Subcontracting. Responses shall be:  RFI Sought number ;  no more than ten (10) pages in length;  not submit marketing materials;  submitted to the email as indicated above. FDA makes no implied or in fact contract by issuing this RFI. Acknowledgement of receipt of responses will not be made, nor will respondents be notified of the FDA's view of the information received. Responses received that include a non-disclosure agreement or identify information that is business sensitive will not be accepted. Responses to this notice will not be returned.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-10-1074431/listing.html)
 
Record
SN02185059-W 20100624/100622235852-90acaa375a46ad498a006ee92e5a38b2 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.